Cdkn2a (cyclin-dependent kinase inhibitor 2A) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Cdkn2a (cyclin-dependent kinase inhibitor 2A) Rattus norvegicus
Analyze
Symbol: Cdkn2a
Name: cyclin-dependent kinase inhibitor 2A
RGD ID: 2323
Description: Predicted to have several functions, including MDM2/MDM4 family protein binding activity; NF-kappaB binding activity; and enzyme inhibitor activity. Involved in several processes, including cellular response to glucose stimulus; negative regulation of hepatocyte proliferation; and nervous system development. Localizes to cytoplasm and nucleus. Predicted to colocalize with nuclear body. Used to study carcinoma (multiple); endometrial cancer; pre-malignant neoplasm; rhabdomyosarcoma; and sarcomatoid mesothelioma. Biomarker of hepatocellular carcinoma; hypertension; obesity; and osteoarthritis. Human ortholog(s) of this gene implicated in several diseases, including breast cancer (multiple); hematologic cancer (multiple); melanoma (multiple); nervous system cancer (multiple); and pancreatic cancer (multiple). Orthologous to human CDKN2A (cyclin dependent kinase inhibitor 2A); PARTICIPATES IN altered G1/S transition pathway; G1/S transition pathway; pancreatic cancer pathway; INTERACTS WITH (+)-pilocarpine; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
Type: protein-coding
RefSeq Status: PROVISIONAL
Also known as: alternative reading frame; Arf; CDK4I; cell cycle inhibitor; cell cycle regulator; Cyclin dependent kinase inhibitor 2A (p16 inhibits CDK4); Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; INK4A; MTS1; p16; p16-INK4; p16-INK4a; p16Cdkn2a; p19ARF
RGD Orthologs
Human
Mouse
Bonobo
Pig
Alliance Genes
More Info more info ...
Allele / Splice: Cdkn2a_v1   Cdkn2a_v2  
Is Marker For: Strains:   F344/NRrrc  
Latest Assembly: Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.25103,984,949 - 103,992,143 (-)NCBI
Rnor_6.0 Ensembl5107,823,330 - 107,841,175 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_6.05107,823,323 - 107,832,405 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_5.05111,793,603 - 111,801,220 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Rnor_5.05111,556,970 - 111,557,193 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.45108,908,749 - 108,916,380 (-)NCBIRGSC3.4rn4RGSC3.4
RGSC_v3.15108,913,974 - 108,921,606 (-)NCBI
Celera5102,700,552 - 102,707,724 (-)NCBICelera
Cytogenetic Map5q32NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
adenocarcinoma  (ISO)
Adrenal Gland Neoplasms  (ISO)
adrenocortical carcinoma  (ISO)
adult hepatocellular carcinoma  (ISO)
B-lymphoblastic leukemia/lymphoma  (ISO)
bladder urothelial carcinoma  (ISO)
bone disease  (ISO)
Brain Neoplasms  (ISO)
Brain Stem Neoplasms  (ISO)
breast cancer  (ISO)
Breast Neoplasms  (ISO)
Carcinogenesis  (ISO)
cervix uteri carcinoma in situ  (ISO)
cholangiocarcinoma  (ISO)
Chromosome Deletion  (ISO)
chronic myeloid leukemia  (ISO)
Colonic Neoplasms  (IEP)
Colorectal Neoplasms  (ISO)
cutaneous T cell lymphoma  (ISO)
diffuse large B-cell lymphoma  (ISO)
disease of cellular proliferation  (ISO)
dysplastic nevus syndrome  (ISO)
endometrial cancer  (IAGP)
Endometrial Neoplasms  (ISO)
esophageal carcinoma  (ISO)
Esophageal Neoplasms  (IEP,ISO)
esophagus adenocarcinoma  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Arthritis  (ISO)
Experimental Leukemia  (ISO)
familial melanoma  (ISO)
Fluoride Poisoning  (ISO)
gastric adenocarcinoma  (ISO)
genetic disease  (ISO)
Genetic Translocation  (ISO)
Germ Cell and Embryonal Neoplasms  (ISO)
germinoma  (ISO)
glaucoma  (ISO)
glioblastoma  (ISO)
granulosa cell tumor  (ISO)
head and neck squamous cell carcinoma  (ISO)
hepatocellular carcinoma  (IDA,IEP,ISO)
Hereditary Neoplastic Syndromes  (ISO)
high grade glioma  (ISO)
Hyperplasia  (IEP)
hypertension  (IEP)
in situ carcinoma  (ISO)
invasive ductal carcinoma  (ISO)
Kidney Neoplasms  (ISO)
leiomyosarcoma  (ISO)
leukemia  (ISO)
Liver Neoplasms  (ISO)
lung adenocarcinoma  (ISO)
Lung Neoplasms  (IDA,ISO)
lung non-small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
lymphoma  (ISO)
malignant mesothelioma  (ISO)
Mammary Neoplasms, Experimental  (IEP,ISO)
melanoma  (ISO)
melanoma and neural system tumor syndrome  (ISO)
Melanoma-Pancreatic Cancer Syndrome  (ISO)
Mesothelioma  (IAGP,ISO)
Micronuclei, Chromosome-Defective  (ISO)
Mouth Neoplasms  (ISO)
multiple myeloma  (ISO)
myelodysplastic syndrome  (ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (ISO)
nephroblastoma  (ISO)
Nerve Sheath Neoplasms  (ISO)
neurilemmoma  (ISO)
neuroblastoma  (ISO)
obesity  (IEP)
osteoarthritis  (IEP)
osteosarcoma  (ISO)
Ovarian Neoplasms  (ISO)
pancreatic adenocarcinoma  (ISO)
pancreatic cancer  (ISO)
pancreatic carcinoma  (ISO)
pancreatic ductal carcinoma  (ISO)
papillary renal cell carcinoma  (ISO)
papillomavirus infectious disease  (ISO)
peripheral nervous system disease  (ISO)
persistent hyperplastic primary vitreous  (ISO)
plasmacytoma  (ISO)
Poisoning  (ISO)
pre-malignant neoplasm  (IDA,ISO)
Premature Aging  (ISO)
prostate adenocarcinoma  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
renal cell carcinoma  (IAGP,ISO)
retinoblastoma  (ISO)
rhabdomyosarcoma  (IDA)
sarcomatoid mesothelioma  (IAGP)
schizophrenia  (ISO)
Sezary's disease  (ISO)
skin melanoma  (ISO)
Sporadic Papillary Renal Cell Carcinoma  (ISO)
squamous cell carcinoma  (ISO)
Stomach Neoplasms  (ISO)
T-cell acute lymphoblastic leukemia  (ISO)
T-cell lymphoblastic leukemia/lymphoma  (ISO)
thymoma  (ISO)
Tongue Neoplasms  (IAGP,IEP)
transient cerebral ischemia  (ISO)
transitional cell carcinoma  (ISO)
Trisomy  (ISO)
urinary bladder cancer  (ISO)
Urogenital Neoplasms  (ISO)
uterine carcinosarcoma  (ISO)
Uterine Cervical Neoplasms  (ISO)
Vulvar Lichen Sclerosus  (ISO)
Vulvar Neoplasms  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (EXP)
(-)-epigallocatechin 3-gallate  (ISO)
(S)-nicotine  (ISO)
(Z)-3-butylidenephthalide  (ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
17beta-estradiol  (ISO)
17beta-hydroxy-17-methylestra-4,9,11-trien-3-one  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dinitrotoluene  (EXP)
2-acetamidofluorene  (EXP)
3-chloropropane-1,2-diol  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-phenylbutyric acid  (ISO)
4-vinylcyclohexene dioxide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (EXP,ISO)
5-fluorouracil  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
ammonium chloride  (EXP)
amosite asbestos  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (EXP,ISO)
asbestos  (ISO)
belinostat  (ISO)
benzene  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzo[b]fluoranthene  (ISO)
beryllium atom  (EXP)
beryllium dihydride  (EXP)
beryllium sulfate  (ISO)
beryllium(0)  (EXP)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
BMS-754807  (ISO)
busulfan  (ISO)
Butylbenzyl phthalate  (ISO)
butyric acid  (ISO)
C60 fullerene  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
caffeine  (ISO)
calcium dichloride  (EXP)
cannabidiol  (EXP,ISO)
capecitabine  (ISO)
capsaicin  (ISO)
carbon nanotube  (ISO)
carmustine  (ISO)
casticin  (ISO)
chloramphenicol  (ISO)
chloroethene  (ISO)
chromium atom  (ISO)
chromium(6+)  (EXP,ISO)
chymostatin  (ISO)
cisplatin  (ISO)
clofibric acid  (EXP)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
cordycepin  (EXP)
corticosterone  (EXP)
crocidolite asbestos  (ISO)
curcumin  (ISO)
cycloheximide  (ISO)
D-glucose  (ISO)
daunorubicin  (ISO)
DDT  (EXP)
dehydroepiandrosterone  (EXP)
Deoxycorticosterone acetate  (EXP)
Diacetoxyscirpenol  (ISO)
diarsenic trioxide  (EXP,ISO)
dibutyl phthalate  (ISO)
dichloroacetic acid  (ISO)
dichromic acid  (ISO)
dichromium trioxide  (ISO)
diethyl phthalate  (ISO)
diisobutyl phthalate  (ISO)
diisononyl phthalate  (ISO)
dimethylarsinic acid  (EXP,ISO)
dioscin  (ISO)
disodium selenite  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
entinostat  (EXP)
etoposide  (EXP,ISO)
fenbendazole  (EXP)
ferric oxide  (ISO)
fluoxetine  (ISO)
folic acid  (ISO)
fumonisin B1  (ISO)
furan  (EXP)
gamma-tocopherol  (ISO)
glucaric acid  (ISO)
glucose  (ISO)
glycidol  (EXP)
glycine betaine  (EXP)
glyphosate  (ISO)
GW 3965  (ISO)
harmine  (ISO)
hexachlorobenzene  (EXP)
hydralazine  (EXP,ISO)
hydrochlorothiazide  (EXP)
hydrogen peroxide  (ISO)
hydroxyurea  (ISO)
irbesartan  (ISO)
irinotecan  (ISO)
isocyanates  (ISO)
L-ascorbic acid  (EXP)
lead diacetate  (ISO)
lidocaine  (ISO)
linalool  (ISO)
lithium chloride  (ISO)
losartan  (ISO)
LY294002  (ISO)
maneb  (EXP)
masoprocol  (ISO)
Mecamylamine  (ISO)
menadione  (ISO)
menaquinone  (ISO)
mercury dibromide  (ISO)
methimazole  (EXP)
methoxyacetic acid  (ISO)
methoxychlor  (ISO)
methylmercury chloride  (EXP,ISO)
methylseleninic acid  (ISO)
microcystin RR  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monobenzyl phthalate  (ISO)
monoethyl phthalate  (ISO)
monosodium L-glutamate  (EXP,ISO)
myo-inositol hexakisphosphate  (ISO)
N-acetyl-L-cysteine  (ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-ethyl-N-nitrosourea  (ISO)
N-methyl-4-phenylpyridinium  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
nickel dichloride  (EXP)
nickel subsulfide  (EXP)
nicotinamide  (ISO)
nicotine  (ISO)
nitrogen dioxide  (EXP)
O-methyleugenol  (EXP)
ochratoxin A  (ISO)
oxaliplatin  (ISO)
p-menthan-3-ol  (ISO)
palbociclib  (ISO)
paracetamol  (ISO)
paraquat  (EXP)
parathion  (ISO)
perfluorooctanoic acid  (ISO)
phenethyl caffeate  (EXP)
phenobarbital  (ISO)
phenylmercury acetate  (ISO)
PhIP  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
pirinixic acid  (ISO)
piroxicam  (EXP)
potassium dichromate  (ISO)
prednisone  (ISO)
procainamide  (ISO)
promethazine  (EXP)
quercetin  (EXP,ISO)
quinoline  (ISO)
radon atom  (ISO)
radon(0)  (ISO)
reserpine  (EXP)
resveratrol  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
salubrinal  (EXP)
SB 203580  (ISO)
SB 431542  (ISO)
silver(1+) nitrate  (ISO)
simvastatin  (EXP)
sodium arsenate  (ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (ISO)
sodium fluoride  (ISO)
spironolactone  (EXP)
stavudine  (ISO)
streptozocin  (ISO)
sulforaphane  (ISO)
sulfur dioxide  (EXP)
sulindac  (EXP)
T-2 toxin  (EXP)
terephthalic acid  (EXP)
tetrachloromethane  (ISO)
thioacetamide  (EXP)
thioridazine  (ISO)
titanium dioxide  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
urethane  (ISO)
valproic acid  (ISO)
vincristine  (ISO)
vinorelbine  (ISO)
wogonin  (ISO)
zearalenone  (ISO)
zidovudine  (ISO)
zinc pyrithione  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
activation of cysteine-type endopeptidase activity involved in apoptotic process  (ISO)
aging  (IEP,ISO)
amyloid fibril formation  (ISO)
apoptotic mitochondrial changes  (ISO)
apoptotic process  (IEA)
autophagy of mitochondrion  (ISO)
cell aging  (ISO)
cellular response to glucose stimulus  (IEP)
cellular response to hydrogen peroxide  (ISO)
cellular senescence  (ISO)
cerebellum development  (IEP)
epidermis development  (ISO)
G1/S transition of mitotic cell cycle  (ISO)
glucose homeostasis  (ISO)
mitochondrial depolarization  (ISO)
negative regulation of B cell proliferation  (ISO)
negative regulation of cell cycle  (ISO)
negative regulation of cell growth  (ISO)
negative regulation of cell population proliferation  (IEA,ISO)
negative regulation of cell-matrix adhesion  (ISO)
negative regulation of cyclin-dependent protein serine/threonine kinase activity  (ISO)
negative regulation of hepatocyte proliferation  (IMP)
negative regulation of immature T cell proliferation in thymus  (ISO)
negative regulation of mammary gland epithelial cell proliferation  (ISO)
negative regulation of NF-kappaB transcription factor activity  (ISO)
negative regulation of phosphorylation  (ISO)
negative regulation of protein binding  (ISO)
negative regulation of protein kinase activity  (ISO)
negative regulation of protein neddylation  (ISO)
negative regulation of proteolysis involved in cellular protein catabolic process  (ISO)
negative regulation of transcription, DNA-templated  (ISO)
negative regulation of ubiquitin protein ligase activity  (ISO)
negative regulation of ubiquitin-dependent protein catabolic process  (ISO)
negative regulation of ubiquitin-protein transferase activity  (ISO)
neurogenesis  (IEP)
positive regulation of apoptotic process  (IMP,ISO,ISS)
positive regulation of apoptotic process involved in mammary gland involution  (ISO)
positive regulation of cellular senescence  (ISO)
positive regulation of DNA damage response, signal transduction by p53 class mediator  (ISO)
positive regulation of DNA-binding transcription factor activity  (ISO)
positive regulation of gene expression  (ISO)
positive regulation of macrophage apoptotic process  (ISO)
positive regulation of protein localization to nucleus  (ISO)
positive regulation of protein sumoylation  (ISO)
positive regulation of signal transduction by p53 class mediator  (ISO)
positive regulation of smooth muscle cell apoptotic process  (ISO)
positive regulation of transcription by RNA polymerase II  (ISO)
positive regulation of transcription, DNA-templated  (ISO)
protein destabilization  (ISO)
protein K63-linked ubiquitination  (ISO,ISS)
protein polyubiquitination  (ISO,ISS)
protein stabilization  (ISO)
Ras protein signal transduction  (ISO)
regulation of apoptotic DNA fragmentation  (ISO)
regulation of cell cycle  (ISO)
regulation of cyclin-dependent protein serine/threonine kinase activity  (ISO)
regulation of DNA-binding transcription factor activity  (ISO)
regulation of G2/M transition of mitotic cell cycle  (ISO)
regulation of gene expression  (ISO)
regulation of nucleocytoplasmic transport  (ISO)
regulation of protein export from nucleus  (ISO)
regulation of protein stability  (ISO)
regulation of protein targeting to mitochondrion  (ISO)
replicative senescence  (ISO)
response to caloric restriction  (IEP)
response to drug  (IDA,IEP)
response to fatty acid  (IEP)
response to organic cyclic compound  (IDA)
response to organic substance  (IEP)
response to organonitrogen compound  (IDA)
response to salt stress  (IEP)
rRNA processing  (IEA)
rRNA transcription  (ISO)
senescence-associated heterochromatin focus assembly  (ISO)
somatic stem cell division  (ISO)
somatic stem cell population maintenance  (ISO)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
1. Adamovic T, etal., Cancer Genet Cytogenet. 2008 Jul;184(1):9-21.
2. Arcellana-Panlilio MY, etal., Genes Chromosomes Cancer. 2002 Oct;35(2):176-81.
3. Askari M, etal., Mol Biol Rep. 2013 Aug;40(8):4921-8. doi: 10.1007/s11033-013-2592-5. Epub 2013 May 28.
4. Bagnyukova TV, etal., Carcinogenesis. 2008 Jan 19;.
5. Bai H, etal., Mutat Res. 2003 Feb 5;535(1):73-8.
6. Belinsky SA, etal., Carcinogenesis 2002 Feb;23(2):335-9.
7. Benevolo M, etal., Mod Pathol. 2006 Mar;19(3):384-91.
8. Borg A, etal., J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6.
9. Buchynska LG and Nesina IP, Exp Oncol. 2006 Jun;28(2):152-5.
10. Bulten J, etal., Gynecol Oncol. 2006 Jun;101(3):487-94. Epub 2006 Jan 9.
11. Cheong C, etal., Mech Ageing Dev. 2006 Jul;127(7):633-8. Epub 2006 Apr 18.
12. Chidlow G, etal., PLoS One. 2013 Sep 19;8(9):e75067. doi: 10.1371/journal.pone.0075067. eCollection 2013.
13. Chien WW, etal., Leuk Res. 2015 Apr;39(4):453-61. doi: 10.1016/j.leukres.2015.01.008. Epub 2015 Jan 25.
14. Cividin M, etal., Leuk Res. 2006 Oct;30(10):1273-8. Epub 2006 Mar 14.
15. de Koning MN, etal., Mod Pathol. 2008 Jan 11;.
16. de Torre C and Martinez-Escribano J, Exp Dermatol. 2010 Aug;19(8):e333-5. doi: 10.1111/j.1600-0625.2009.01048.x.
17. Debies MT, etal., J Clin Invest. 2008 Jan;118(1):51-63.
18. Debniak T, etal., J Med Genet. 2005 Oct;42(10):763-5. Epub 2005 May 6.
19. Diaz-Rodriguez E, etal., Oncogene. 2012 Jun 7;31(23):2824-35. doi: 10.1038/onc.2011.458. Epub 2011 Oct 24.
20. Eliason MJ, etal., J Invest Dermatol. 2006 Mar;126(3):660-6.
21. Faderl S, etal., Cancer. 2000 Nov 1;89(9):1976-82.
22. Fasseu M, etal., Blood. 2007 Oct 1;110(7):2610-9. Epub 2007 May 16.
23. Focchi GR, etal., J Low Genit Tract Dis. 2007 Apr;11(2):98-104.
24. Fong LY, etal., Cancer Res. 2000 Aug 15;60(16):4589-95.
25. Fujii H, etal., Biochem Biophys Res Commun. 2007 Oct 26;362(3):773-8. Epub 2007 Aug 22.
26. Gannon BR, etal., Int J Gynecol Pathol. 2008 Jan;27(1):68-73.
27. Geradts J and Wilson PA, Am J Pathol. 1996 Jul;149(1):15-20.
28. Guillerm G, etal., Haematologica. 2003 Apr;88(4):476-8.
29. Harashima M, etal., Biomed Res. 2013;34(5):269-73.
30. Hashemi J, etal., Melanoma Res. 1999 Feb;9(1):21-30.
31. Hauer J, etal., Blood. 2011 Jul 21;118(3):544-53. doi: 10.1182/blood-2010-09-305383. Epub 2011 May 26.
32. Heidenreich A, etal., J Urol. 1998 May;159(5):1725-30.
33. Herman JG, etal., Cancer Res. 1996 Feb 15;56(4):722-7.
34. Hiroyasu M, etal., Am J Pathol 2002 Feb;160(2):419-24.
35. Hong Y, etal., Mol Carcinog. 2007 Feb;46(2):85-90.
36. Hong Y, etal., Oral Oncol. 2009 Jul;45(7):640-4. doi: 10.1016/j.oraloncology.2008.06.007. Epub 2008 Sep 18.
37. Hu Q, etal., Lab Invest. 2010 Mar;90(3):360-73. doi: 10.1038/labinvest.2009.140. Epub 2010 Jan 11.
38. Hung KS, etal., Biochem Biophys Res Commun. 2000 Mar 24;269(3):718-25.
39. Iizuka D, etal., Radiat Res. 2010 Aug;174(2):206-15. doi: 10.1667/RR2006.1.
40. Integration of LocusLink data, October 12, 2001
41. Ishikawa A, etal., Hum Pathol. 2004 Dec;35(12):1505-14.
42. Jones S, etal., Science. 2008 Sep 26;321(5897):1801-6. Epub 2008 Sep 4.
43. Kang S, etal., Diagn Mol Pathol. 2006 Jun;15(2):74-82.
44. Kannan K, etal., Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1221-5. Epub 2003 Jan 21.
45. Kasahara T, etal., Anticancer Res. 2006 Nov-Dec;26(6B):4299-305.
46. Katchanov J, etal., J Neurosci. 2001 Jul 15;21(14):5045-53.
47. Kawaguchi T, etal., Int J Oncol. 2014 Jun;44(6):1879-85. doi: 10.3892/ijo.2014.2372. Epub 2014 Apr 7.
48. Kawamoto K, etal., Biochem Biophys Res Commun. 2006 Jan 20;339(3):790-6. Epub 2005 Nov 22.
49. Kiss NB, etal., Endocr Relat Cancer. 2008 Jun;15(2):609-21. doi: 10.1677/ERC-07-0285.
50. Kommoss S, etal., Br J Cancer. 2007 Jan 29;96(2):306-13.
51. Kostka G, etal., Toxicology. 2007 Sep 24;239(1-2):127-35. Epub 2007 Jul 12.
52. Kovalenko VM, etal., Toxicol Appl Pharmacol. 2007 Dec 15;225(3):293-9. Epub 2007 Aug 23.
53. Kozlova EN and Lukanidin E, Glia 2002 Mar 15;37(4):337-48.
54. Krishnamurthy J, etal., J Clin Invest 2004 Nov;114(9):1299-307.
55. Labuhn M, etal., Oncogene. 2001 Mar 1;20(9):1103-9.
56. Laharanne E, etal., Mod Pathol. 2010 Apr;23(4):547-58. doi: 10.1038/modpathol.2009.196. Epub 2010 Jan 29.
57. Lau WM, etal., Oncogene. 2007 Sep 6;26(41):6050-60. Epub 2007 Mar 19.
58. Liu WB, etal., Toxicol Lett. 2009 Aug 25;189(1):5-13. doi: 10.1016/j.toxlet.2009.04.022. Epub 2009 May 3.
59. Louhelainen M, etal., J Physiol Pharmacol. 2009 Sep;60(3):41-7.
60. Maestro de las Casas ML, etal., Arch Esp Urol. 2000 Sep;53(7):603-9.
61. Maloney KW, etal., Blood. 1999 Apr 1;93(7):2380-5.
62. Maloney KW, etal., Leukemia. 1997 Jul;11(7):979-83.
63. Mariappan MM, etal., Am J Physiol Renal Physiol. 2011 Jan;300(1):F219-30. doi: 10.1152/ajprenal.00207.2010. Epub 2010 Oct 13.
64. Marsit CJ, etal., Ann N Y Acad Sci. 2006 Sep;1076:810-21.
65. MGD data from the GO Consortium
66. Monsonego J, etal., Acta Cytol. 2007 Sep-Oct;51(5):755-66.
67. Morey SR, etal., Cancer Res. 2006 Dec 15;66(24):11659-67.
68. Nagao M, etal., J Cell Biol. 2008 Dec 29;183(7):1243-57. doi: 10.1083/jcb.200807130.
69. Nakao M, etal., Leukemia. 1996 Feb;10(2):249-54.
70. Natrajan R, etal., J Clin Pathol. 2008 Jan;61(1):95-102. Epub 2007 Mar 16.
71. NCBI rat LocusLink and RefSeq merged data July 26, 2002
72. Nielsen GP, etal., Am J Pathol 1999 Dec;155(6):1879-84.
73. Nogueira MC, etal., Pathol Oncol Res. 2006;12(3):153-7. Epub 2006 Sep 23.
74. O'Neill CJ, etal., Histopathology. 2007 May;50(6):773-9.
75. Ogawa K, etal., Oral Oncol. 2006 Mar 7;.
76. OMIM Disease Annotation Pipeline
77. Park TJ, etal., Mol Carcinog. 2001 Mar;30(3):138-50.
78. Pascale RM, etal., Hepatology. 2005 Dec;42(6):1310-9.
79. Pipeline to import KEGG annotations from KEGG into RGD
80. Platz A, etal., J Natl Cancer Inst. 1997 May 21;89(10):697-702.
81. Pogribny IP and James SJ, Cancer Lett. 2002 Dec 10;187(1-2):69-75.
82. RGD automated data pipeline
83. RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
84. RGD automated import pipeline for gene-chemical interactions
85. RGD comprehensive gene curation
86. Robinson-Bennett B, etal., Int J Gynecol Cancer. 2006 May-Jun;16(3):1354-7.
87. Rodrigues EF, etal., Leuk Lymphoma. 2010 Oct;51(10):1887-94. doi: 10.3109/10428194.2010.505820.
88. Romanenko A, etal., Virchows Arch. 2004 Sep;445(3):298-304. Epub 2004 Jul 1.
89. Shank-Calvo JA, etal., Oncogene. 2006 May 18;25(21):3023-31.
90. Sharma G, etal., Life Sci. 2007 Apr 24;80(20):1873-81. Epub 2007 Feb 27.
91. Sherr CJ Cancer Res. 2000 Jul 15;60(14):3689-95.
92. Soufir N, etal., Mol Carcinog. 2004 Apr;39(4):195-8.
93. Sugimoto M, etal., Mol Cell 2003 Feb;11(2):415-24.
94. Swafford DS, etal., Mol Cell Biol 1997 Mar;17(3):1366-74.
95. Taniguchi K, etal., Nat Med. 1999 Jul;5(7):760-7.
96. Tao L, etal., Carcinogenesis. 2002 Sep;23(9):1447-54.
97. Toncheva D and Zaharieva B, Tumour Biol. 2005 Mar-Apr;26(2):88-93. Epub 2005 May 13.
98. Treiber N, etal., Aging Cell. 2011 Apr;10(2):239-54. doi: 10.1111/j.1474-9726.2010.00658.x. Epub 2010 Dec 29.
99. Tschan MP, etal., Leuk Lymphoma. 2001 Sep-Oct;42(5):1077-87.
100. Volanakis EJ, etal., Blood. 2009 Nov 12;114(20):4451-9. doi: 10.1182/blood-2009-07-233346. Epub 2009 Sep 16.
101. Volanakis EJ, etal., Exp Hematol. 2013 Apr;41(4):377-86. doi: 10.1016/j.exphem.2012.11.006. Epub 2012 Nov 23.
102. Wang D, etal., Biol Pharm Bull. 2012;35(12):2128-32.
103. Wang TJ, etal., Biochem Biophys Res Commun. 2001 Sep 14;287(1):173-80.
104. Watanabe G, etal., Brain Res Dev Brain Res. 1998 Jun 15;108(1-2):77-87.
105. Westhoff JH, etal., Hypertension. 2008 Jul;52(1):123-9. Epub 2008 May 26.
106. Wiley A, etal., Cancer. 2006 Jul 15;107(2):299-308.
107. Williams RT, etal., Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93. Epub 2006 Apr 17.
108. Wu G, etal., Int J Mol Med. 2013 Nov;32(5):1001-10. doi: 10.3892/ijmm.2013.1481. Epub 2013 Sep 4.
109. Xu H, etal., Nat Commun. 2015 Jun 24;6:7553. doi: 10.1038/ncomms8553.
110. Yao Q, etal., Zhonghua Nan Ke Xue. 2006 Jan;12(1):28-31.
111. Yin M, etal., Hum Pathol. 2008 Apr;39(4):527-35. Epub 2008 Jan 30.
112. Zhang G, etal., J Tradit Chin Med. 2012 Dec;32(4):651-6.
113. Zhang J, etal., Biomed Environ Sci. 2011 Apr;24(2):163-71. doi: 10.3967/0895-3988.2011.02.011.
114. Zhang SL, etal., Mol Cell Biol. 2001 Jan;21(1):310-8.
115. Zhang X, etal., Am J Physiol Gastrointest Liver Physiol. 2012 Mar 1;302(5):G558-64. doi: 10.1152/ajpgi.00032.2011. Epub 2011 Dec 22.
116. Zhang Y, etal., Cancer. 2011 Mar 15;117(6):1227-35. doi: 10.1002/cncr.25605. Epub 2010 Nov 8.
117. Zhang Z, etal., Mod Pathol. 2006 Oct;19(10):1339-43. Epub 2006 Jun 23.
118. Zheng S, etal., Epigenetics. 2012 Feb;7(2):183-90. doi: 10.4161/epi.7.2.18972.
Additional References at PubMed
PMID:7603984   PMID:7651726   PMID:7739547   PMID:8259215   PMID:9054499   PMID:9529249   PMID:9878046   PMID:10205165   PMID:10208428   PMID:10353611   PMID:10360174   PMID:11438662  
PMID:11551927   PMID:11718560   PMID:11748239   PMID:11800646   PMID:12082630   PMID:12130539   PMID:12154087   PMID:12417039   PMID:12630860   PMID:14720514   PMID:14966292   PMID:15105443  
PMID:15144691   PMID:15149599   PMID:15201967   PMID:15355988   PMID:15485902   PMID:15567177   PMID:15582998   PMID:15964995   PMID:15989966   PMID:16173922   PMID:16199867   PMID:16243918  
PMID:16760664   PMID:16901784   PMID:17110379   PMID:17310983   PMID:17569660   PMID:18019407   PMID:18305112   PMID:18396777   PMID:18560357   PMID:18625840   PMID:18656278   PMID:18704299  
PMID:18809582   PMID:18818403   PMID:18957199   PMID:19057511   PMID:19255859   PMID:19642983   PMID:20381282   PMID:20808772   PMID:20934317   PMID:21911473   PMID:22094112   PMID:22320862  
PMID:22681889   PMID:22729085   PMID:22873822   PMID:22952318   PMID:22984612   PMID:23277542   PMID:24616519   PMID:25217637   PMID:25865695   PMID:27323397   PMID:29166374   PMID:31687322  
PMID:32080953   PMID:33010296  


Genomics

Candidate Gene Status
Cdkn2a is a candidate Gene for QTL Emca11
Comparative Map Data
Cdkn2a
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.25103,984,949 - 103,992,143 (-)NCBI
Rnor_6.0 Ensembl5107,823,330 - 107,841,175 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_6.05107,823,323 - 107,832,405 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_5.05111,793,603 - 111,801,220 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Rnor_5.05111,556,970 - 111,557,193 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.45108,908,749 - 108,916,380 (-)NCBIRGSC3.4rn4RGSC3.4
RGSC_v3.15108,913,974 - 108,921,606 (-)NCBI
Celera5102,700,552 - 102,707,724 (-)NCBICelera
Cytogenetic Map5q32NCBI
CDKN2A
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38.p13 Ensembl921,967,752 - 21,995,301 (-)EnsemblGRCh38hg38GRCh38
GRCh38.p13 Ensembl921,967,753 - 21,995,301 (-)EnsemblGRCh38hg38GRCh38
GRCh38921,967,752 - 21,995,324 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh37921,967,751 - 21,995,323 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36921,957,751 - 21,984,490 (-)NCBINCBI36hg18NCBI36
Build 34921,957,751 - 21,984,490NCBI
Celera921,906,103 - 21,932,858 (-)NCBI
Cytogenetic Map9p21.3NCBI
HuRef921,930,969 - 21,957,759 (-)NCBIHuRef
CHM1_1921,967,646 - 21,994,319 (-)NCBICHM1_1
Cdkn2a
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39489,192,710 - 89,212,856 (-)NCBIGRCm39mm39
GRCm39 Ensembl489,192,708 - 89,212,890 (-)Ensembl
GRCm38489,274,473 - 89,294,619 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl489,274,471 - 89,294,653 (-)EnsemblGRCm38mm10GRCm38
MGSCv37488,920,377 - 88,940,523 (-)NCBIGRCm37mm9NCBIm37
MGSCv36488,745,868 - 88,765,796 (-)NCBImm8
Celera487,760,902 - 87,780,610 (-)NCBICelera
Cytogenetic Map4C4NCBI
cM Map442.15NCBI
CDKN2A
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.1922,420,748 - 22,447,243 (-)NCBIpanpan1.1PanPan1.1panPan2
Mhudiblu_PPA_v0921,803,862 - 21,831,322 (-)NCBIMhudiblu_PPA_v0panPan3
P14ARF
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1200,774,496 - 200,798,854 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11200,774,496 - 200,799,149 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21223,989,828 - 223,992,651 (-)NCBISscrofa10.2Sscrofa10.2susScr3

Position Markers
D5Lev17  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.25103,991,975 - 103,992,098 (+)MAPPER
Rnor_6.05107,832,238 - 107,832,360NCBIRnor6.0
Rnor_5.05111,801,053 - 111,801,175UniSTSRnor5.0
RGSC_v3.45108,916,213 - 108,916,335UniSTSRGSC3.4
Celera5102,707,557 - 102,707,679UniSTS
Cytogenetic Map5q32UniSTS
PMC152255P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.25103,991,982 - 103,992,130 (+)MAPPER
Rnor_6.05107,832,245 - 107,832,392NCBIRnor6.0
Rnor_5.05111,801,060 - 111,801,207UniSTSRnor5.0
RGSC_v3.45108,916,220 - 108,916,367UniSTSRGSC3.4
Celera5102,707,564 - 102,707,711UniSTS
Cytogenetic Map5q32UniSTS


QTLs in Region (Rnor_6.0)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
70212Niddm25Non-insulin dependent diabetes mellitus QTL 253.54blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)51136640934Rat
634305Mamtr1Mammary tumor resistance QTL 10.0001mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)512651967117554267Rat
2290448Scl54Serum cholesterol level QTL 542.93blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)531926122136640934Rat
1576317Eutr2Estrogen induced uterine response QTL 20.01uterus integrity trait (VT:0010575)pyometritis severity score (CMO:0002009)535225432108092802Rat
2316959Gluco59Glucose level QTL 594.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)535661945117554267Rat
1641912Alcrsp18Alcohol response QTL 18response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)535788756147487820Rat
1549845Scl44Serum cholesterol level QTL 446blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)540777918154732375Rat
1331801Rf33Renal function QTL 334.149kidney blood vessel physiology trait (VT:0100012)absolute change in renal vascular resistance (CMO:0001900)544404276134502294Rat
1578766Tcas11Tongue tumor susceptibility QTL 114.12tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)547745646167946134Rat
1576312Emca8Estrogen-induced mammary cancer QTL 84.1mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)551418671147487820Rat
70189Mcs5Mammary carcinoma susceptibility QTL 510.51mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)556991667137729065Rat
1358895Bp254Blood pressure QTL 2543.60.0003arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)560072951133313852Rat
61426Scl2Serum cholesterol level QTL 27.30.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)561086525149030144Rat
2316957Pur21Proteinuria QTL 216.2urine protein amount (VT:0005160)urine protein level (CMO:0000591)561086653117554114Rat
61393Bp7Blood pressure QTL 74.50.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)561612600168109659Rat
2306971Anxrr21Anxiety related response QTL 219.47fear/anxiety-related behavior trait (VT:1000241)number of entries into a discrete space in an experimental apparatus (CMO:0000960)565696672129038896Rat
2290005Mcs24Mammary carcinoma susceptibility QTL 24mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)568838385113838385Rat
1357396Bw44Body weight QTL 444.19body mass (VT:0001259)body weight (CMO:0000012)571154828108092802Rat
1357402Bw46Body weight QTL 464.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)571154828108092802Rat
2312671Scl64Serum cholesterol level QTL 640.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)571154828108092802Rat
2302381Bw84Body weight QTL 844.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)571154828108092802Rat
61380Edpm5Estrogen-dependent pituitary mass QTL 54.50.92pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)571154828108092802Rat
1354598Srn6Serum renin concentration QTL 63.8blood renin amount (VT:0003349)plasma renin activity level (CMO:0000116)571552569157225114Rat
1298070Scl18Serum cholesterol level QTL 183.7blood LDL cholesterol amount (VT:0000181)calculated plasma low density lipoprotein cholesterol level (CMO:0001245)583424556128424556Rat
1598846Bp293Blood pressure QTL 2933.9arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)583424556128424556Rat
1598859Cm66Cardiac mass QTL 662heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)583424556128424556Rat
1302790Scl20Serum cholesterol level QTL 206.40.0001blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)584963058173504662Rat
1298086Bp156Blood pressure QTL 156arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)589502294134502294Rat
7411582Foco3Food consumption QTL 37.50.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)591585539136585539Rat
7411601Foco12Food consumption QTL 1219.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)591585539136585539Rat
7411564Bw135Body weight QTL 1350.001body mass (VT:0001259)body weight gain (CMO:0000420)591585539136585539Rat
6903316Bw113Body weight QTL 11320.0103body mass (VT:0001259)body weight (CMO:0000012)591884213136884213Rat
1358889Bp261Blood pressure QTL 2612.86arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)593037304133313852Rat
1358909Kidm25Kidney mass QTL 251.87kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)593037304133313852Rat
631527Tls1T-lymphoma susceptibility QTL 100.001thymus integrity trait (VT:0010555)post-insult time to onset of T-cell lymphoma (CMO:0001907)593273130138273130Rat
61452Ciaa5CIA Autoantibody QTL 53.5blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)597921932149030144Rat
1331796Thshl2Thyroid stimulating hormone level QTL 22.3blood thyroid-stimulating hormone amount (VT:0005119)serum thyroid stimulating hormone level (CMO:0001248)5100723739153577831Rat
2317753Glom24Glomerulus QTL 243.1kidney glomerulus integrity trait (VT:0010546)kidney sclerotic glomeruli count to total glomeruli count ratio (CMO:0001269)5101265591141912026Rat
1582212Livw2Liver weight QTL 23.50.0004liver mass (VT:0003402)liver weight as percentage of body weight (CMO:0000141)5102498468123852688Rat
1358187Emca1Estrogen-induced mammary cancer QTL 14.4mammary gland integrity trait (VT:0010552)post-insult time to mammary tumor formation (CMO:0000345)5102945579154732228Rat
7394708Emca11Estrogen-induced mammary cancer QTL 11mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)5103580245117037276Rat
1578673Bmd13Bone mineral density QTL 134.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)5107119214152119214Rat


Related Rat Strains
The following Strains have been annotated to Cdkn2a

miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:62
Count of miRNA genes:60
Interacting mature miRNAs:61
Transcripts:ENSRNOT00000066011
Prediction methods:Microtar, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium
Low 2 16 14 22 5
Below cutoff 19 14 14 5 14 2 3 7 5 13 6 2

Sequence

Nucleotide Sequences
RefSeq Transcripts NM_031550 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
GenBank Nucleotide AB081658 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474974 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474975 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474976 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474977 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY145882 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY679727 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY679728 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  CH473998 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ336094 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ336095 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ336096 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ350894 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ350895 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ350896 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  JACYVU010000162 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  L81167 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles

Reference Sequences
RefSeq Acc Id: ENSRNOT00000079251   ⟹   ENSRNOP00000072063
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl5107,823,374 - 107,841,175 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000084293   ⟹   ENSRNOP00000073038
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl5107,823,330 - 107,832,405 (-)Ensembl
RefSeq Acc Id: NM_031550   ⟹   NP_113738
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.25103,984,949 - 103,992,143 (-)NCBI
Rnor_6.05107,823,323 - 107,832,405 (-)NCBI
Rnor_5.05111,556,970 - 111,557,193 (-)NCBI
Rnor_5.05111,793,603 - 111,801,220 (-)NCBI
RGSC_v3.45108,908,749 - 108,916,380 (-)RGD
Celera5102,700,552 - 102,707,724 (-)RGD
Sequence:
Reference Sequences
RefSeq Acc Id: NP_113738   ⟸   NM_031550
- UniProtKB: Q9R0Z3 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: ENSRNOP00000072063   ⟸   ENSRNOT00000079251
RefSeq Acc Id: ENSRNOP00000073038   ⟸   ENSRNOT00000084293
Protein Domains
ANK_REP_REGION

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13693832
Promoter ID:EPDNEW_R4357
Type:multiple initiation site
Name:Cdkn2a_2
Description:cyclin-dependent kinase inhibitor 2A
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R4358  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.05107,832,373 - 107,832,433EPDNEW
RGD ID:13693836
Promoter ID:EPDNEW_R4358
Type:multiple initiation site
Name:Cdkn2a_1
Description:cyclin-dependent kinase inhibitor 2A
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R4357  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.05107,841,191 - 107,841,251EPDNEW

Strain Variation

Strain Sequence Variants (Rnor 6.0)
ACI/EurMcwi (MCW)
Visual CSV TAB Printer
Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob)
Platform: Illumina HiSeq 2000
Secondary Analysis: BWA v0.7.7 and GATK v3.2-2
Breeder: Medical College of Wisconsin
Description: Provided by the Medical College of Wisconsin (Dr. Howard Jacob)
ACI/EurMcwi (RGD)
Visual CSV TAB Printer
Platform: Illumina HiSeq 2000
Secondary Analysis: BWA mem 0.7.15, GATK v.3.6-0
Description: Sequences from Atanur et al and Hermsen et al realigned to the Rnor 6.0 assembly and reanalyzed by RGD
ACI/N (MCW)
Visual CSV TAB Printer
Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen)
Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner)
Platform: SOLiD 4 and 5500
Secondary Analysis: liftOver (Batch Coordinate Conversion)--genome.ucsc.edu
Breeder: National Institutes of Health
Description: Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
BBDP/Wor (RGD)
Visual CSV TAB Printer
Platform: Illumina HiSeq 2000
Secondary Analysis: BWA mem 0.7.15, GATK v.3.6-0
Description: Sequences from Atanur et al and Hermsen et al realigned to the Rnor 6.0 assembly and reanalyzed by RGD
BN/SsN (MCW)
Visual CSV TAB Printer
Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen)
Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner)
Platform: SOLiD 4 and 5500
Secondary Analysis: liftOver (Batch Coordinate Conversion)--genome.ucsc.edu
Breeder: National Institutes of Health
Description: Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Buf/N (MCW)
Visual CSV TAB Printer
Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen)
Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner)
Platform: SOLiD 4 and 5500
Secondary Analysis: liftOver (Batch Coordinate Conversion)--genome.ucsc.edu
Breeder: National Institutes of Health
Description: Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
COP/CrCrl (MCW & UW)
Visual CSV TAB Printer
Sequenced By: Medical College of Wisconsin (Dr. Howard Jacob)
University of Wisconsin (Dr. James Shull)
Platform: Illumina HiSeq 2000
Secondary Analysis: BWA v0.7.7 and GATK v3.2-2
Breeder: Charles River Laboratories
Description: Provided by the Medical College of Wisconsin (Dr. Howard Jacob) and UW Madison (Dr. James Shull)
F344/NCrl (RGD)
Visual CSV TAB Printer
Platform: Illumina HiSeq 2000
Secondary Analysis: BWA mem 0.7.15, GATK v.3.6-0
Description: Sequences from Atanur et al and Hermsen et al realigned to the Rnor 6.0 assembly and reanalyzed by RGD
F344/NRrrc (MCW)
Visual CSV TAB Printer
Sequenced By: Royal Netherland Academy of Arts and Sciences (Dr. Edwin Cuppen)
Max Delbruck Center for Molecular Medicine (Dr. Norbert Huebner)
Platform: SOLiD 4 and 5500
Secondary Analysis: liftOver (Batch Coordinate Conversion)--genome.ucsc.edu
Breeder: National Institutes of Health
Description: Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
FHH/EurMcwi (MCW)
Visual CSV TAB